- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 213/02
Total number of patents in this class: 197
10-year publication summary
|
13
|
8
|
8
|
14
|
8
|
11
|
6
|
8
|
14
|
12
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4656 |
9 |
| Bristol-myers Squibb Company | 4878 |
5 |
| Nocion Therapeutics, Inc. | 42 |
5 |
| Pillai Universal LLC | 14 |
5 |
| Aerpio Therapeutics, Inc. | 21 |
4 |
| Merck Sharp & Dohme LLC | 3750 |
4 |
| Hoffmann-La Roche Inc. | 3414 |
3 |
| BASF SE | 20926 |
3 |
| Genentech, Inc. | 3971 |
3 |
| Dana-Farber Cancer Institute, Inc. | 2567 |
3 |
| Universal Display Corporation | 1904 |
3 |
| The Procter & Gamble Company | 22016 |
2 |
| Merck Sharp & Dohme Corp. | 2197 |
2 |
| Vertex Pharmaceuticals Incorporated | 1599 |
2 |
| University of Florida Research Foundation, Inc. | 4018 |
2 |
| Akebia Therapeutics, Inc. | 113 |
2 |
| Amira Pharmaceuticals, Inc. | 70 |
2 |
| Melinta Therapeutics, Inc. | 50 |
2 |
| RespiVert Ltd. | 78 |
2 |
| Trustees of Tufts College | 877 |
2 |
| Other owners | 132 |